Present Data News Today

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Alireza Faridar, the Stanley H. Appel Chair in Translational...

Investegate announcements from PureTech Health PLC, Gelesis Presents New Data at ObesityWeek 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7, 2022, Amryt...

North America region emerged as the largest market for the Inflammatory Bowel Disease Treatment market with around 51.5% share of the market revenue in 2020.

Cabaletta Bio Inc. (CABA) is priced at $1.25 after the most recent trading session. At the very opening of the session, the stock price was $1.89 and reached a high price of $2.10, prior to closing the session it reached the value of $1.90. The stock touched a low price of $1.10.Recently in News on

IMARC Group expects the market to reach a value of US$ 16.8 Billion by 2027, exhibiting a CAGR of 9.40% during 2022-2027.

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022  DUBLIN, Ireland, and...

17.05.2022 - New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori) infection Phathom research recognized with multiple ... Seite 1